Merck & Co., Inc. (MRK)
| Market Cap | 281.05B |
| Revenue (ttm) | 58.97B |
| Net Income (ttm) | 15.26B |
| Shares Out | 2.53B |
| EPS (ttm) | 6.03 |
| PE Ratio | 18.04 |
| Forward PE | 14.56 |
| Dividend | $2.76 (2.54%) |
| Ex-Dividend Date | Dec 14, 2022 |
| Volume | 9,090,362 |
| Open | 110.98 |
| Previous Close | 110.85 |
| Day's Range | 108.75 - 111.37 |
| 52-Week Range | 71.97 - 111.37 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 112.55 (+3.5%) |
| Earnings Date | Oct 27, 2022 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions an... [Read more]
Financial Performance
In 2021, Merck & Co.'s revenue was $48.70 billion, an increase of 17.31% compared to the previous year's $41.52 billion. Earnings were $13.05 billion, an increase of 84.65%.
Financial StatementsAnalyst Forecast
According to 32 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is 112.55, which is an increase of 3.47% from the latest price.
News
Merck (MRK) Is Up 2.36% in One Week: What You Should Know
Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Final Trades: Stryker, Southwest Gas, Freeport-McMoRan & more
The "Halftime Report" traders give their top picks to watch for the second half.
4 Defensive Stocks to Prepare Your Portfolio for a Recession
Amid the rising possibility of a recession, defensive stocks with solid prospects will cushion investors from market jitters while their robust fundamentals ensure higher returns. ADM, HSY, UNH and MRK ...
3 High-Yielding Stocks That Are Up 27%-Plus This Year
Is it too late to buy these soaring stocks?
Is Merck Stock A Buy After Surging To A Fresh High On Its Imago Buyout Plans?
Is Merck stock a buy after the company announced its acquisition of Imago, a bone marrow diseases company? Is MRK stock a buy now?
Should Investors Consider These 3 Low-Beta Stocks?
During times of heightened volatility, adding low-beta stocks can help blend in an extra layer of portfolio defense.
Top 4 Blue-Chip Stocks to Enhance Your Portfolio in December
We have narrowed our search to four Dow stocks. These are: CAT, WMT, MRK, UNH.
Hot Fund To SEC: We're Boosting Bets On Best Stock Picks
Wondering how to invest in stocks and mutual funds amid a grim market? Red-hot Invesco Comstock Select Fund is doubling down on its strategy.
3 Reasons Growth Investors Will Love Merck (MRK)
Merck (MRK) could produce exceptional returns because of its solid growth attributes.
3 Stocks to Watch That Recently Announced Dividend Hikes
Merck & Co., Inc. (MRK), McCormick & Company, Incorporated (MKC) and Tsakos Energy Navigation Limited (TNP) recently hiked dividends.
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology...
RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from clinical trials and real-world studies at the ...
Gurus Prescribed These Health Care Stocks in the 3rd Quarter
Amid rising concerns about the state of the global economy, rising inflation, central bank interest rate hikes and increased Covid-19 restrictions in China, marked indexes were mixed on Wednesday morning.
Three-Stock Lunch: PayPal, Merck and Broadcom
Quint Tatro, Joule Financial founder and CEO, joins 'Power Lunch' to discuss his investing take on three stocks: PayPal, Merck and Broadcom.
Merck Announces First-Quarter 2023 Dividend
RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.73 per share...
At All-Time Highs, Merck's Stock Is Nearing a Cliff
Throughout the beginning of the Covid-19 pandemic, pharmaceutical companies were mostly focused on the availability and effectiveness of vaccines. However, around December 2021, the focus shifted more t...
Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
3 Dow Stocks to Take Seriously in 2023
The Dow Jones Industrial Average is down more than 6% year-to-date. With slightly more than half of the index in negative territory for the year, it is easier to come up with three of the top Dow stocks...
Merck & Co., Inc. (MRK) Hits Fresh High: Is There Still Room to Run?
Merck (MRK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Biotech Stocks Smart Investors Should Be Buying Up Now
For investors looking for growth, biotech stocks are a great place to start one's search. This is a sector that's seen its valuation multiples decline in many cases to a greater extent than the overall ...
Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal
Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.
IMAGO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Ade...
NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Imago BioScience...
3 Undervalued Dow Stocks to Buy Before Wall Street Catches On
The Dow Jones Industrial Average is down around 6.2% year to date. Of the 30 stocks in the index, 14 are down at least 10% for the year.
Buy These 5 Corporate Giants Flying High in Disappointing 2022
We have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.
Japan approves COVID antiviral pill as Pfizer, Merck alternative
TOKYO—Japan approved an antiviral pill from Shionogi & Co. to treat Covid-19 after the company provided new data to show the drug's efficacy.
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gas...
RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 KEYNOTE-859 trial investigatin...